Wu Wurihan, Mao Hejun, Song Jian, Yang Fan
Department of Neurology Department, Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China.
Department of Hepatobiliary Surgery, Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China.
Medicine (Baltimore). 2025 May 16;104(20):e42015. doi: 10.1097/MD.0000000000042015.
Hepatocellular carcinoma (HCC) is a common malignant tumor globally and in China, and its incidence and mortality rate are increasing year by year, and it faces many challenges and difficulties in treatment. Tyrosine kinase inhibitors (TKIs) have important roles in cell growth, proliferation, and differentiation, and have now become important drugs for cancer treatment. There are no bibliometric studies on liver cancer and TKIs to date.
We retrieved 2848 records from the Web of Science™ Core Collection (WoSCC) database and analyzed them scientifically and metrically using CiteSpace and VOSviewer in terms of temporal and spatial distributions, author distributions, journal distributions, references, and keywords.
From January 1, 2004, to December 31, 2023, the WoSCC database documented 2848 publications related to tyrosinase inhibitors in HCC, comprising 2151 articles and 697 reviews. This literature involved 80 countries and regions, 3265 institutions, and 16,653 authors. Analysis shows a steady increase in publications annually since 2004, divided into 3 phases: 2004 to 2010 with fewer than 100 papers annually, suggesting minimal research attention; 2011 to 2019 with gradual growth, indicating increasing research interest; and a rapid surge post-2020, peaking in 2023, signaling heightened global interest in this field.
Our bibliometric analysis on TKIs and HCC spans years, countries, institutions, authors, disciplines, and journals. Since 2004, this field has gained attention, with current research focusing on inflammatory and immune mechanisms, associated diseases, cytokines, and TKIs' applications in liver cancer treatment, including combination therapies. These areas signify emerging research directions.
肝细胞癌（HCC）是全球及中国常见的恶性肿瘤，其发病率和死亡率逐年上升，在治疗上面临诸多挑战和困难。酪氨酸激酶抑制剂（TKIs）在细胞生长、增殖和分化中发挥重要作用，现已成为癌症治疗的重要药物。迄今为止，尚无关于肝癌和TKIs的文献计量学研究。
我们从科学网核心合集（WoSCC）数据库中检索到2848条记录，并使用CiteSpace和VOSviewer从时间和空间分布、作者分布、期刊分布、参考文献和关键词等方面进行科学计量分析。
从2004年1月1日至2023年12月31日，WoSCC数据库记录了2848篇与HCC中酪氨酸酶抑制剂相关的出版物，其中包括2151篇文章和697篇综述。这些文献涉及80个国家和地区、3265个机构以及16653名作者。分析表明，自2004年以来，出版物数量逐年稳步增加，分为三个阶段：2004年至2010年，每年发表的论文少于100篇，表明研究关注度较低；从2011年至2019年逐渐增长，表明研究兴趣不断增加；2020年后迅速激增，在2023年达到峰值，表明全球对该领域的兴趣增强。
我们对TKIs和HCC的文献计量分析涵盖了年份、国家、机构、作者、学科和期刊。自2004年以来，该领域受到了关注，当前的研究重点是炎症和免疫机制、相关疾病、细胞因子以及TKIs在肝癌治疗中的应用，包括联合治疗。这些领域标志着新兴的研究方向。
